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80The ratio of cystatin C (cysC) to creatinine (crea) is regarded as a marker of
glomerular filtration quality associated with cardiovascular morbidities. We sought
to determine reference intervals for serum cysC-crea ratio in seniors. Furthermore,
we sought to determine whether other low–molecular weight molecules exhibit a
similar behavior in individuals with altered glomerular filtration quality. Finally, we
investigatedassociationswithadverse outcomes.A total of 1382 subjectively healthy
Swiss volunteers aged 60 years or older were enrolled in the study. Reference inter-
vals were calculated according to Clinical & Laboratory Standards Institute (CLSI)
guideline EP28-A3c. After a baseline exam, a 4-year follow-up survey recorded infor-
mation about overall morbidity and mortality. The cysC-crea ratio (mean
0.01246 0.0026mg/mmol) was significantly higher in womenand increased progres-
sively with age. Other associated factors were hemoglobin A1c, mean arterial pres-
sure, and C-reactive protein (P , 0.05 for all). Participants exhibiting shrunken pore
syndrome had significantly higher ratios of 3.5–66.5 kDa molecules (brain natriuretic
peptide, parathyroid hormone, b2-microglobulin, cystatin C, retinol-binding protein,
thyroid-stimulating hormone, a1-acid glycoprotein, lipase, amylase, prealbumin,
and albumin) and creatinine. There was no such difference in the ratios of very
low–molecular weight molecules (urea, uric acid) to creatinine or in the ratios of
molecules larger than 66.5 kDa (transferrin, haptoglobin) to creatinine. The cysC-
crea ratio was significantly predictive of mortality and subjective overall morbidity
at follow-up in logistic regression models adjusting for several factors. The cysC-
crea ratio exhibits age- and sex-specific reference intervals in seniors. In conclusion,
the cysC-crea ratio may indicate the relative retention of biologically active low–
molecular weight compounds and can independently predict the risk for overall
mortality and morbidity in the elderly. (Translational Research 2016;169:80–90)Abbreviations: BMI¼ bodymass index; BNP¼ brain natriuretic peptide; BUN¼ blood urea nitro-
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The human body clears the blood of substances
66 kDa and smaller by glomerular filtration. The
structure of the glomerular filtration barrier is com-
plex, and there is no generally accepted 3-D model
available.1 Creatinine is the most readily used endog-
enous marker for estimating the glomerular filtration
rate (GFR), but serum creatinine is influenced by a
number of nonrenal factors, such as age, sex, muscle
mass, and diet.2-4 Creatinine is a 113 Da breakdown
product of creatine phosphate in muscle and is
produced at a fairly constant rate; it is freely filtered
across the glomerular membrane, actively secreted
in tubules, and is not reabsorbed.5 When GFR de-
creases, the tubular secretion of creatinine increases;
therefore, a mild degree of kidney dysfunction
(,50% reduction in GFR) will not increase the serum
creatinine concentration above the upper limit of
normal values.6
Compared with creatinine, cystatin C is better corre-
latedwithGFRand is amore accurate predictor of several
clinical outcomes.7-9 Cystatin C is a 13.3 kDa cysteineprotease inhibitor produced by all nucleated cells.10 It
is freely filtered across the glomerular membrane,
reabsorbed, and catabolized by the tubules.11-13 The
serum level of cystatin C is also influenced by nonrenal
factors, such as steroid medication and thyroid
dysfunction.14,15 However, the cystatin C concentration
is considered a better predictor of adverse outcomes
compared with directly measured GFR, and this may be
because these nonrenal influences enable a superior
estimate of actual kidney function.16
Because the levels of the 2 markers are affected by
different nonrenal factors, their ratio varies. The ratio
of cystatin C and creatinine in serum (cysC-crea ratio)
is substantially increased in a condition called
‘‘shrunken pore syndrome’’, which is characterized by
very different GFR estimates based on the 2 markers
(eGFRCys# 60% eGFRCrea).
1 Shrinking of the glomer-
ular pores is thought to occur in certain conditions, for
example, pregnancy, and is particularly pronounced in
cases of preeclampsia.1,17 Although GFR initially
remains normal (and even increases in normal
pregnancy), the composition of the glomerular filtrate
changes because larger molecules can no longer pass
through the pores.18 Consequently, the serum concen-
trations of larger molecules increase. Because cystatin
C is larger than creatinine, its plasma levels begin to in-
crease first.19,20 Therefore, an increased cysC-crea ratio
indicates a change in glomerular filtration quality that
suggests early-stage kidney dysfunction.
The present work aimed to define factors associated
with the cysC-crea ratio.We also evaluated reference in-
tervals for this ratio in the elderly. Furthermore, we
aimed to explore whether other low–molecular weight
molecules display a similar behavior to cystatin C rela-
tive to creatinine. Finally, we investigated the cysC-crea
ratio as a predictor of morbidity and mortality in healthy
elderly individuals.METHODS
Study population. The present study was conducted
within the framework of the SENIORLAB study, the
primary aim of which is to establish reference intervals
for several laboratory parameters for the elderly (www.
seniorlabor.ch). The study consecutively enrolled
subjectively healthy elderly volunteers from May
2009 to December 2011. Potential study participants
were contacted through newspaper advertisements,
various associations with high proportions of healthy
Fig 1. Chart representing all recruited participants, including those excluded from the study (n5 number of par-
ticipants). *One participant fulfilled 2 exclusion criteria. BMI, body mass index; CRP, C-reactive protein.
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personal contacts of the study collaborators. Inclusion
criteria were as follows: age of at least 60 years, resi-
dence in Switzerland, and a subjective perception of
health. The exclusion criteria for the present study
were as follows: current steroid use, thyroid dysfunction
(free-thyroxin level ,9 or .19 pmol/L), C-reactive
protein (CRP) concentration above 10 mg/L, and
underweight (body mass index [BMI] ,18.5 kg/m2).
The patient inclusion process is illustrated in Fig 1.
The exclusion criteria were applied to reduce
confounding nonrenal influences on creatinine and
cystatin C.21 We considered underweight a surrogate
marker for low–muscle mass and/or inadequate
nutrition. The study was conducted in accordance with
the Code of Ethics of the World Medical Association
(Declaration of Helsinki) and was approved by the
responsible institutional review board (Kantonale
Ethikkommission Bern). Written informed consent
was obtained from all patients participating in the study.
Data collection. The participants’ personal histories
and anthropometric measurements, such as height and
weight, were collected at the baseline exam. Blood pres-
sure was measured in a sitting position after a 10-minute
rest. Venous blood was drawn into S-Monovettes
(Sarstedt, Sevelen, Switzerland) after an overnight
fasting period. Blood samples were processed
(centrifuged, aliquoted, and analyzed or frozen at
280C) immediately to enable standardized
preanalytics. A follow-up survey recorded information
about subjective well-being and mortality. Overall
morbidity was defined as a negative answer to the
question of whether the patient was feeling healthy.For the follow-up examination, study participants
were contacted by mail and telephone. In case of a
lack of response, official communal authorities,
relatives, and/or neighbors were contacted.
Laboratory methods. Laboratory parameters were
determined using various analytical platforms. Serum
cystatin C levels were assessed using a nephelometric
method on a Siemens ProSpec (Siemens, Zurich,
Switzerland) and standardized to the International
Federation of Clinical Chemistry and Laboratory
Medicine standard, as described by Inker et al22,23
The isotope dilution mass spectrometry (IDMS)-
standardized serum creatinine concentration was
determined by a modified Jaffe method on a Cobas
Integra 800 instrument (Roche Diagnostics, Risch-
Rotkreuz, Switzerland). Commercially available
materials were used for quality control. The interday
coefficients of variation were as follows: 3.75% at
0.37 mg/L and 3.43% at 0.44 mg/L for cystatin C and
4.27% at 42 mmol/L and 1.96% at 556 mmol/L for
creatinine. The levels of high-sensitivity CRP, retinol-
binding protein, a1-acid glycoprotein, and haptoglobin
were determined on a Siemens ProSpec (Siemens).
The hemoglobin A1c level was assessed by high-
performance liquid chromatography (Bio-Rad D-10;
Pratteln, Switzerland). Total cholesterol, low density
lipoprotein (LDL) cholesterol, high density
lipoprotein (HDL) cholesterol, blood urea nitrogen
(BUN), uric acid, lipase, pancreatic amylase,
prealbumin, and transferrin were measured on a Cobas
Integra 800, whereas brain natriuretic peptide (BNP)
and thyroid-stimulating hormone (TSH) were assessed
using an Architect i4000 instrument (Abbott, Baar,
Translational Research
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microglobulin were assayed by an Immulite 2000
analyzer (Diagnostics Products Corporation, DPC;
B€uhlmann Laboratories, Allschwil, Switzerland).
Estimated GFR (eGFR) was calculated according to
Nyman et al by calculating the arithmetic mean between
eGFRCys (as obtained from the Caucasian, Asian,
Pediatrics, and Adults cohort’s, CAPA equation) and
eGFRCrea (as obtained from the Lund-Malm€o revised
equation, i.e. LMrev; eGFRCAPA1LMrev ).
24-26 This
average eGFRCAPA1LMrev has been shown to display a
better diagnostic performance in a European
population than the combined Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI 2012)
equation.27 In the article by Bj€ork et al,27,28 it has
also been shown that even when eGFRCys and
eGFRCrea differ considerably, the average generally
remains a very good estimate of measured GFR. In
addition, to estimate the prevalence and sequelae of
shrunken pore syndrome, eGFRCys and eGFRCrea were
calculated separately according to the CKD-EPI
equations and according to the LMrev equation
(for eGFRCrea) and the CAPA (for eGFRCys) equa-
tion.25,26,29,30
Statistical analysis. We used several descriptive and
inferential statistical methods. To evaluate the univari-
ate associations between continuous variables,
Spearman rank correlations were used. Continuous vari-
ables were compared using the Mann-Whitney U test
for correlations between 2 groups and using the
Kruskal-Wallis test for correlations among 3 or more
groups. Proportions were compared using the c2 test.
Double-sided 95% reference intervals for the cysC-
crea ratio were calculated for participants with eGFR
.60 mL/min/1.73 m2 and eGFRCys differing by less
than 40% from eGFRCrea by using the robust method,
as recommended by the Clinical & Laboratory Stan-
dards Institute (CLSI) guideline EP28-A3c.31 The
criteria of eGFR,60 mL/min/1.73 m2 and the presence
of shrunken pore syndromewere applied to exclude par-
ticipants with overt kidney disease from reference inter-
val determination.1,21 Outliers were eliminated
according to Dixon and Reed et al.31-33
To determine whether molecules with different mo-
lecular weights are handled differently in patients with
shrunken pore syndrome, the ratios of BUN (60 Da),
uric acid (168 Da), BNP (3.5 kDa), PTH (9.4 kDa),
b2-microglobulin (11.7 kDa), cystatin C (13.3 kDa),
retinol-binding protein (20.6 kDa), TSH (28 kDa), a1-
acid glycoprotein (40 kDa), lipase (47 kDa), prealbumin
(55 kDa), pancreatic amylase (55.4 kDa), albumin
(66.5 kDa), transferrin (78 kDa), and haptoglobin
(.100 kDa) to creatinine were compared between par-
ticipants with shrunken pore syndrome and controlsmatched for age (62 years), sex, and eGFR (68 mL/
min/1.73 m2).34
Linear regression models were fitted to evaluate the
factors associated with the cysC-crea ratio. Here, several
factors known to carry a cardiovascular risk were
included as covariates. Finally, logistic regressionmodels
were fitted to evaluate predictors of overall morbidity at
follow-up. Coxmultivariate proportional hazards models
were used to determine independent predictors ofmortal-
ity. Finally, survival rates during follow-up were esti-
mated by Kaplan-Meier curves for participants with
and without shrunken pore syndrome, and comparisons
were made by log-rank test. A sensitivity analysis using
different methods of eGFRCys/eGFRCrea estimation
(CKD-EPI vs CAPA/LMrev) and different cutoffs (60%,
70%, and 80%) was used; P, 0.05 was considered sig-
nificant. All calculations were performed with MedCalc
version 14.12.0 (Mariakerke, Belgium) and Excel 2010
(Microsoft, Seattle, Wash). Figures were drawn with
PowerPoint (Microsoft) and GraphPad Prism 5.04
(GraphPad Software, La Jolla, Calif).RESULTS
Baseline characteristics. A total of 1382 participants
with a mean age of 71.9 6 7.8 years and a female pro-
portion of 53.1% (734 females, 648 males) were
included in the present analysis. The detailed character-
istics of the study population are presented in Table I
and reflect the expected spectrum of subjectively
healthy seniors. Follow-up for survival after a mean of
3.7 6 0.7 years was available for all participants
(100%), and follow-up for morbidity was missing for
only 0.4% (n 5 5) of the surviving participants. At
follow-up, 129 participants (9.3%) reported overall
morbidity, and 58 participants (4.2%) died within the
follow-up period after 2.2 6 1.2 years.
The mean cysC-crea ratio was 0.0124 6 0.0026 mg/
mmol. There was a significant correlation between the
cysC-crea ratio and age (r 5 0.33; P , 0.001). Males
had significantly lower ratios than females
(0.0111 6 0.0019 vs 0.0136 6 0.0024 mg/mmol;
P , 0.001). The ratio of cystatin C–based eGFR to
creatinine-based eGFR (eGFRCys/eGFRCrea) was higher
in males (1.07 6 0.18) than that in females
(1.04 6 0.17; P 5 0.001) when CKD-EPI equations
were used. The sex difference was different when using
the CAPA and LMrev equations (1.186 0.19 in males vs
1.21 6 0.19 in females; P 5 0.01).
Shrunken pore syndrome, defined by Grubb et al1 as
an eGFRCys ,60% of eGFRCrea, was observed in 10
participants (0.7%) by using the CKD-EPI equations.
The participants with eGFRCys/eGFRCrea ,0.6 were
significantly older than those with eGFRCys/eGFRCrea
Table I. Detailed characteristics of the investigated
cohort
Characteristic Mean 6 SD or % (n)
Female 53.1 (734)
Age (y) 71.9 6 7.8
BMI (kg/m2) 25.5 6 3.7
Systolic blood pressure (mmHg) 149 6 23
Diastolic blood pressure (mmHg) 90 6 13
Mean arterial pressure (mmHg) 110 6 15
Pulse pressure (mmHg) 58 6 16
Hemoglobin A1c (%) 5.9 6 0.6
Antihypertensive use 37.8 (523)
Current smoker 6.7 (93)
Cholesterol (mmol/L) 5.75 6 1.13
LDL cholesterol (mmol/L) 3.77 6 1.04
HDL cholesterol (mmol/L) 1.66 6 0.46
Creatinine (mmol/L) 77 6 19
Cystatin C (mg/L) 0.93 6 0.22
Cystatin C/creatinine (mg/mmol) 0.0124 6 0.0026
CKD-EPI eGFRCys 1 Crea (mL/min/1.73 m
2) 81 6 16
CKD-EPI eGFRCys (mL/min/1.73 m
2) 81 6 19
CKD-EPI eGFRCrea (mL/min/1.73 m
2) 78 6 14
eGFRCAPA1LMrev (mL/min/1.73 m
2) 76 6 14
CAPA eGFRCys (mL/min/1.73 m
2) 82 6 18
LMrev eGFRCrea (mL/min/1.73 m
2) 69 6 13
BNP (pg/mL) 72 6 112
CRP (mg/L) 1.86 6 1.83
Abbreviations: BMI, body mass index; BNP, brain natriuretic pep-
tide;CRP, C-reactive protein; eGFR, estimated glomerular filtration
rate; LMrev, Lund-Malm€o revised equation; SD, standard deviation.
The mean 6 SD is given when appropriate.
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these 10 participants, 3 (30%) died, and 5 of the remain-
ing 6 (83%; 1 with missing information) reported over-
all morbidity. Compared with participants with
eGFRCys/eGFRCrea .0.6, participants with shrunken
pore syndrome showed significantly higher morbidity
and mortality (P, 0.01). When the CAPA/LMrev equa-
tions were used, the prevalence of shrunken pore syn-
drome was lower than estimated with the CKD-EPI
equations (3/1382; 0.2%). The distributions of the
eGFRCys/eGFRCrea, as estimated by CKD-EPI and
CAPA/LMrev equations, are given in Supplementary
Fig 1 together with the prevalence of shrunken pore syn-
drome at different cutoffs for eGFRCys/eGFRCrea.
Furthermore, the distributions of the ratios between cys-
tatin C and creatinine are also given.
Reference intervals. Reference intervals for the cysC-
crea ratio were stratified according to age and sex. Fe-
males displayed higher values than those of males,
and the lower and upper limits of the reference intervals
increased with advancing age. Detailed reference inter-
vals are presented in Table II. Respective reference
intervals for CKD-EPI eGFRCys/eGFRCrea and CAPA/
LMrev estimates of eGFRCys/eGFRCrea are provided in
Supplementary Tables I and II.Associated factors. Several risk factors for cardiovas-
cular disease were investigated for univariate associa-
tions with the cysC-crea ratio (Table III). There were
no significant differences in the cysC-crea ratio
because of current smoking (P 5 0.24), anamnestic
hypertension (P 5 0.73), or antihypertensive drug use
(P 5 0.11). Conventional cardiovascular risk factors,
with the exception of hemoglobin A1c and current
smoking, were associated with the cysC-crea ratio in
univariate analysis.
A linear regression model including the cysC-crea ra-
tio as the dependent variable and several cardiovascular
risk factors (age, sex, BMI, mean arterial pressure, pulse
pressure, hemoglobin A1c, current smoking, HDL
cholesterol, LDL cholesterol, eGFR, BNP, and CRP)
as independent variables explained 37% of the
variability (adjusted R2) of the ratio. All predictors
had a low variance inflation factor (,2), indicating
the absence of collinearity in this model. Age
(P , 0.001), male sex (P , .001), hemoglobin A1c
(P 5 0.002), mean arterial pressure (P 5 0.048), and
CRP (P , 0.001) were significant predictors of the
cysC-crea ratio. HDL cholesterol (P 5 0.058), BNP
(P5 0.06), and pulse pressure (P5 0.08) were border-
line significant predictors, whereas BMI (P 5 0.55),
eGFRCAPA1LMrev (P 5 0.49), current smoking
(P 5 0.13), and LDL cholesterol (P 5 0.28) were not
predictive.
Behavior of other low–molecular weightmolecules. The
10 participants with shrunken pore syndrome had
significantly higher molecule-to-creatinine ratios
compared with the 40 controls matched for age, sex,
and kidney function for molecules with a molecular
weight between 3.5 and 66.5 kDa (Fig 2). There were
no significant differences regarding age (85;
interquartile range, [78–89] vs 85.5 [78–89] years),
sex (20/40 males vs 5/10 males), BMI (24.9 [22.8–
27.5] vs 24.3 [22.0–27.2] kg/m2), CRP (1.93 [0.77–
3.70] vs 1.86 [1.47–2.46] mg/L), or eGFR (54 [46–61]
vs 53 [44–60] mL/min/1.73 m2) between the controls
and the cases. Interestingly, there were no such
differences in these ratios for molecules with a
molecular weight less than 200 Da or greater than
66.5 kDa (Table IV). The proteins displaying higher
ratios relative to creatinine belong to the functional
families of hormones, transport proteins, enzymes,
kidney function markers, and acute phase reactants.
Predictivity for overall morbidity. Participants reporting
morbidity after a mean of 3.7 6 0.7 years of follow-up
after reporting well-being at baseline had significantly
higher cysC-crea ratios than those who remained well
(0.0130 6 0.003 vs 0.01231 6 0.0024 mg/mmol;
P 5 0.004). A logistic regression model with
morbidity at follow-up as the outcome variable and
Table II. Reference intervals for the serum cysC-crea ratio (mg/mmol) stratified according to age and sex
Age
Females Males
Subjects Lower limit Upper limit Subjects Lower limit Upper limit
60–64 130 0.009 (0.0087–0.0094) 0.0157 (0.0153–0.0161) 126 0.0072 (0.0068–0.0076) 0.0131 (0.0127–0.0135)
65–69 173 0.0088 (0.0084–0.0092) 0.0168 (0.0163–0.0173) 154 0.0073 (0.0069–0.0077) 0.0137 (0.0132–0.0141)
70–74 147 0.0092 (0.0087–0.0098) 0.0173 (0.0167–0.0179) 139 0.0082 (0.0079–0.0086) 0.0135 (0.0132–0.0139)
75–79 106 0.0093 (0.0085–0.0102) 0.0181 (0.0173–0.0189) 87 0.0071 (0.0063–0.0078) 0.0147 (0.0140–0.0155)
80–84 66 0.0105 (0.0097–0.0113) 0.0193 (0.0183–0.0202) 61 0.0085 (0.0079–0.0092) 0.0155 (0.0149–0.0161)
$85 29 0.0090 (0.0075–0.0107) 0.0199 (0.0179–0.0217) 16 0.0079 (0.0067–0.0095) 0.0167 (0.0148–0.0182)
Upper and lower limits are provided with 90% confidence intervals in parentheses.
Table III. Spearman correlation coefficients (r) for
the serum cysC-crea ratio and several
cardiovascular risk factors
Parameter r P value
Age (y) 0.33 ,0.001
BMI (kg/m2) 20.092 ,0.001
Systolic blood pressure (mmHg) 0.08 0.005
Diastolic blood pressure (mmHg) 0.06 0.02
Mean arterial pressure (mmHg) 0.07 0.006
Pulse pressure (mmHg) 0.05 0.08
Hemoglobin A1c (%) 0.01 0.60
Cholesterol (mmol/L) 0.11 ,0.001
LDL cholesterol (mmol/L) 0.09 0.001
HDL cholesterol (mmol/L) 0.16 ,0.001
eGFRCAPA1LMrev (mL/min/1.73 m
2) 20.15 ,0.001
BNP (pg/mL) 0.32 ,0.001
CRP (mg/L) 0.15 ,0.001
Abbreviations: BMI, body mass index; BNP, brain natriuretic pep-
tide;CRP, C-reactive protein; eGFR, estimated glomerular filtration
rate.
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mmol), systolic as well as diastolic blood pressure
(mm Hg), hemoglobin A1c (%), total cholesterol
(mmol/L), current smoking, CRP (mg/L), BNP (mg/
mL), and eGFRCAPA1LMrev (mL/min/1.73 m
2) as the
predictor variables exhibited a c-statistic of 0.66 (95%
confidence interval [CI], 0.64–0.69). In this model,
hemoglobin A1c (P 5 0.005) and the cysC-crea ratio
(P 5 0.046) were significantly predictive of overall
morbidity at follow-up. The odds ratios for these
significant predictors were 1.41 (95% CI, 1.11–1.81)
for hemoglobin A1c and 1.09 (95% CI, 1.001–1.19)
for the cysC-crea ratio.
Analogous models were fit with eGFRCysC/eGFRCrea
instead of the cysC-crea ratio. For these 2 models, CKD-
EPI equations and the CAPA and LMrev equations,
respectively, were used. Both models revealed only he-
moglobin A1c as a significant predictor for overall
morbidity (P 5 0.008 in both) with an odds ratio of1.40 (95% CI, 1.09–1.79) for the ratio between the
CKD-EPI equations and an odds ratio of 1.39 (95%
CI, 1.09–1.78) for the ratio between CAPA and LMrev
equations. The odds ratios for the eGFRCysC/eGFRCrea
were 1.0 (95% CI, 0.98–1.01) for CKD-EPI and 1.0
(95% CI, 0.99–1.01) for CAPA/LMrev.
Predictivity for overall mortality. The 58 participants
who died within the follow-up period had significantly
higher cysC-crea ratios at baseline compared with the
surviving participants (0.0138 6 0.0035 vs
0.0124 6 0.0025 mg/mmol; P , 0.001). A Cox
proportional hazards regression model with age
(years), sex, eGFRCAPA1LMrev (mL/min/1.73 m
2), and
the cysC-crea ratio (g/mmol) as predictor variables
was significantly predictive of mortality (P , 0.001).
In this model, the cysC-crea ratio (hazard ratio 1.11;
95% CI, 1.03–1.20; P 5 0.007), age (hazard ratio
1.13; 95% CI, 1.08–1.18; P , 0.001), and male
gender (hazard ratio 2.56; 95% CI, 1.46–4.48;
P 5 0.001) were significant independent predictors of
mortality, whereas there was no such association with
eGFRCAPA1LMrev (hazard ratio 0.99; 95% CI, 0.97–
1.01; P 5 0.4).
Adding 1 additional cardiovascular risk factor to the
age, sex, and eGFR-adjusted model for the prediction
of death by the cysC-crea ratio in several models re-
vealed that the significant relationship between the
cysC-crea ratio and overall mortality remained intact
when adjusting for BMI, mean arterial pressure, systolic
blood pressure, diastolic blood pressure, BNP, hemoglo-
bin A1c, known diabetes, CRP, pulse pressure, HDL,
LDL, or current smoking. A Kaplan-Meier survival
analysis for participants exhibiting shrunken pore syn-
drome defined at ,60%, 70%, and 80% eGFRCys/
eGFRCrea showed significantly lower survival in partic-
ipants with shrunken pore syndrome, regardless of
whether the ratio of eGFRCys/eGFRCrea was assessed
by CKD-EPI (n 5 10, P , 0.001 at ,60%; n 5 52, P
, 0.001 at 70%; n 5 92, P , 0.001 at 80%) or the
CAPA and LMrev equations (n 5 3, P 5 0.004 at
Fig 2. Ratios of different molecules to creatinine in participants with and without shrunken pore syndrome. The
ratios were not different between molecules with lower and higher molecular weights. Significant differences are
marked by asterisks. b2-MG, b2-microglobulin; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CysC,
cystatin C; PTH, parathyroid hormone; SPS, shrunken pore syndrome. An asterisk indicates a significant differ-
ence (P , 0.05).
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at 80%).
The survival curves of participants with and without
shrunken pore syndrome according to the differentdefinitions are given in Fig 3. It can be observed that sur-
vival differences become larger when the cutoff for
eGFRCys/eGFRCrea for the definition of shrunken pore
syndrome is decreased. It also becomes apparent that
Table IV. Molecule-to-creatinine ratio (mmol/L) in 10 participants with shrunken pore syndrome (as obtained
with CKD-EPI equations and a cutoff of,60% for definition of the syndrome) and 40 controls matched for age,
sex, and eGFR
Parameter Molecular weight Participants with SPS Participants without SPS P value
Blood urea nitrogen (mmol/L) 60 Da 0.0927 (0.0704–0.105) 0.0785 (0.0699–0.0927) 0.11
Uric acid (mmol/L) 168 Da 4.969 (3.411–5.976) 3.894 (3.331–4.512) 0.08
BNP (pg/mL) 3.5 kDa 1.678 (1.222–5.127) 1.0 (0.567–1.741) 0.03
PTH (pmol/L) 9.4 kDa 0.0918 (0.0721–0.164) 0.061 (0.0457–0.0876) 0.03
b2-microglobulin (mg/L) 11.7 kDa 0.048 (0.0381–0.0571) 0.0264 (0.0225–0.030) ,0.001
Cystatin C (mg/L) 13.3 kDa 0.0217 (0.0176–0.0258) 0.0130 (0.0114–0.0140) ,0.001
RBP (mg/L) 20.6 kDa 0.0687 (0.0623–0.0715) 0.0539 (0.0456–0.0676) 0.03
TSH (U/L) 28 kDa 0.0298 (0.0154–0.0413) 0.0138 (0.0118–0.0287) 0.04
a1-acid glycoprotein (g/L) 40 kDa 0.0097 (0.0091–0.0111) 0.0085 (0.0068–0.0107) 0.04
Lipase (U/L) 47 kDa 0.601 (0.358–0.746) 0.357 (0.274–0.553) 0.04
Prealbumin (g/L) 55 kDa 0.0033 (0.0029–0.0034) 0.0026 (0.0021–0.0030) 0.02
Pancreatic amylase (U/L) 55.4 kDa 0.461 (0.382–0.580) 0.349 (0.203–0.481) 0.049
Albumin (g/L) 66.5 kDa 0.543 (0.519–0.655) 0.453 (0.366–0.519) 0.002
Transferrin (g/L) 78 kDa 0.0312 (0.0264–0.0427) 0.0259 (0.0224–0.0249) 0.13
Haptoglobin (g/L) .100 kDa 0.0150 (0.0111–0.195) 0.0132 (0.0092–0.176) 0.39
Abbreviations: BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; IQR, interquartile range; PTH, parathyroid hormone;
RBP, retinol-binding protein; SPS, shrunken pore syndrome; TSH, thyroid-stimulating hormone.
The ratios are given for different molecules with increasingmolecular weight and are displayed as median and IQR showing the 25th and 75th
percentiles.
Fig 3. Survival curves are given for differences in survival among participants with and without SPS at different
cutoffs of 60% (A andC), 70% (B andE), and 80% (C and F). eGFRCysC and eGFRCrea were estimated with CKD-
EPI equations (A–C) and with CAPA and LMrev equations (D–F). In all comparisons, the survival of participants
with SPS is significantly worse than that of participants without SPS. Ticks represent censored cases. LMrev, Lund-
Malm€o revised equation; SPS, shrunken pore syndrome.
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ferences at a cutoff of 80%, independent of the methods
used for the estimation of GFR.DISCUSSION
This study evaluated the reference intervals of the
serum cystatin C/creatinine ratio in seniors aged 60 years
and older. This ratio increased with advancing age and
was higher in women than in men. Furthermore, the ratioof these 2 kidney functionmarkers predicted overall mor-
tality and morbidity after nearly 4 years of follow-up,
even after adjustment of the regressionmodels for kidney
function and other covariates. Finally, in participantswith
shrunken pore syndrome, molecules with a molecular
weight between 3.5 and 66.5 kDa showed relative reten-
tion similar to that of cystatin C. The proteins displaying
higher ratios to creatinine belong to the functional fam-
ilies of hormones, transport proteins, enzymes, kidney
function markers, and acute phase reactants.
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participants was expected because serum creatinine is
lower in females and older populations.2,14 In a model
adjusted for the measured GFR, Stevens et al14 found
the serum cystatin C concentration to be lower in women
and to decrease with age, although to a lesser extent than
creatinine. Therefore, the age-related increase in the
cysC-crea ratio may partly be explained by an unequal
decrease with age in the levels of markers.
However, other nonrenal factors exert a differential
influence on cystatin C and creatinine.14 The cysC-
crea ratio increases with lower creatinine values and/
or higher cystatin C levels. Lower creatinine levels
occur in the presence of lower body weight, higher
white blood cell count, and lower protein intake.4,14
Higher cystatin C levels have been observed in the
presence of diabetes, higher body weight, higher
systolic blood pressure, and increased markers of
inflammation—all known cardiovascular risk factors.14
The differential behavior of creatinine and cystatin C
may be due to the influence of not only nonrenal factors
but also factors that affect the quality of filtration of
different substances in the glomerulus. Grubb et al1,35
described the decrease in glomerular filtration quality
as a pathophysiological phenomenon occurring
because of the shrinking of the glomerular pores with
subsequent unimpeded filtration of creatinine and the
retention of 3 different low–molecular weight proteins
in serum. This phenomenon suggests morphologic
changes in the kidneys in these states at the
glomerular filtration barrier. The structure of the
glomerular filtration barrier is complex, and there is
no generally accepted 3-D model.1 Consequently, these
morphologic changes—in contrast to biochemical
changes—in shrunken pore syndrome have not yet
been demonstrated by pathoanatomic methods.
It has been hypothesized that glomerular pores shrink
in many renal diseases.1,35 This changes the
composition of glomerular filtrate, but measured GFR
does not decrease. Proteins with a molecular weight
up to approximately 20 kDa are excreted primarily by
glomerular transport.36 Owing to the pore shrinkage,
the larger molecules can no longer traverse glomerular
pores and exit the bloodstream. Therefore, their serum
levels start to increase. A small reduction in pore size
is identified by increased serum concentrations of these
larger molecules. As the pores shrink further, smaller
molecules are also retained and start to accumulate in
the blood. Because cystatin C (13.3 kDa) is.100 times
larger than creatinine (113 Da), it is retained at a much
lower degree of shrinkage and can therefore indicate
kidney disease at an earlier stage.
The ratio of serum cystatin C to creatinine has not yet
been extensively researched. There are sporadic reportson glomerular filtration quality in different collec-
tives.1,35,37,38 To our knowledge, reference intervals
have only been reported for pediatric patients.37 The
present study is the first to provide reference intervals
for the cysC-crea ratio in seniors. In general, both the
lower and upper limits of the reference intervals
increased with age and were higher in the female study
participants. The values observed in the study by Grubb
et al1 arewithin the range observed in our study. Theme-
dian values for patients with shrunken pore syndrome re-
ported by Grubb et al1 and for the 10 participants with
shrunken pore syndrome in the present study are above
the upper limit of the reference intervals for all investi-
gated age classes. We also provided reference intervals
for eGFRCysC/eGFRCrea, which in both our study and
another study performed in patients undergoing elective
coronary artery bypass grafting has been demonstrated
as an independent predictor of mortality.39
The prevalence of shrunken pore syndrome, as
described by Grubb et al,1 is low in the present cohort
of healthy elderly people. However, patients with
shrunkenpore syndrome in our study cohort of healthy se-
niors had a significantly higher prevalence of morbidity
and mortality. Further indication that shrunken pore syn-
dromemight be a risk factor formorbidity can be obtained
from the fact that shrunken pore syndrome occurs signif-
icantly more frequently in hospitalized patients (8.2%)
than in healthy seniors (0.2%; P , 0.0001; c2 test).1
Our analyses have also shown that the prevalence of
shrunken pore syndrome depends on the equations
used for the calculation of eGFRCysC/eGFRCrea. As
demonstrated by others,39 the CKD-EPI formula results
in higher prevalence compared with CAPA and LMrev
equations, which were originally used to characterize
shrunken pore syndrome.1 However, both sets of
equations can indicate an increased risk for mortality.
Interestingly, an increased risk for mortality was also
present when cutoffs higher than the originally
proposed cutoff of ,60% were used for eGFRCysC/
eGFRCrea, irrespective of the equations used. This
observation is in line with the findings of Dashdati
et al39 in patients undergoing elective coronary artery
bypass grafting. The magnitude of survival impairment
in participants of the present study is also comparable
to that observed in patients undergoing elective coronary
artery bypass grafting.39
Interestingly, molecules with a very low–molecular
weight, such as BUN and uric acid, did not show
different filtration behaviors in participants with and
without shrunken pore syndrome.1 This result corrobo-
rates the findings of Grubb et al,1 who hypothesized that
molecules with a very low–molecular weight, such as
creatinine, do not undergo impeded glomerular filtra-
tion in patients with shrunken pore syndrome.
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weight proteins such as cystatin C and b2-microglobulin
are higher in individuals with shrunken pore syndrome
than those in controls with normal glomerular filtration
quality. Our observations indicate that the same
mechanisms leading to their relative retention might
affect not only the levels of kidney function markers
but also of hormones, acute-phase reactants, transport
proteins, and enzymes with a molecular weight up to
66.5 kDa. However, it remains unclear whether the
increased BNP/creatinine, PTH/creatinine, and TSH/
creatinine ratios are due to alterations in glomerular
filtration quality or due to endocrinological feedback
mechanisms.
In summary, we observed increased protein/
creatinine ratios for proteins with a molecular weight
of 3.5–66.5 kDa, which encompasses the range of
molecular weights filtered by the renal glomeruli. We
did not investigate b-trace protein, with a molecular
weight between 23–29 kDa, which has also shown
increased ratios in patients with shrunken pore
syndrome.1 Altogether, in patients with shrunken pore
syndrome, low–molecular weight proteins up to
approximately 66.5 kDa (but not very low–molecular
weight metabolites such as BUN and uric acid) indicate
altered glomerular filtration quality by their relative
retention.
It has already been hypothesized that the discrepant
behavior of creatinine and other markers of GFR may
lead not only to retention of GFR markers but also to in-
creases in other compounds with molecular weights
similar to the low–molecular weight markers of kidney
function, such as interleukin 6 and a variety of other pro-
teins with signaling function (ie, cytokines, hormones,
and growth factors).1 These retained mediators are
thought to lead to increased overall and disease-
specific morbidity and mortality. Our study now demon-
strates the relative retention of such signaling proteins,
that is, BNP and PTH, which both have been shown to
lead to higher all-cause mortality in the general
population.40-42 The relative retention of compounds
other than kidney function markers offers a
pathophysiological link for our observation of
increased overall mortality and decreased well-being.
Several low–molecular weight markers of GFR (ie,
b2-microglobulin, beta-trace protein, and cystatin C)
improve risk prediction compared with creatinine.43
The cysC-crea ratio may thus be a tool by which to
estimate the retention of low–molecular weight
proteins (ie, mediators) relative to creatinine that could
be easily introduced to automatically generated labora-
tory reports.28
The main strengths of the study are its prospective
design, the large number of included participants,complete follow-up, and the use of standardized labora-
tory results for measuring cystatin C and creatinine. All
laboratory analyses were performed on freshly collected
material. One limitation is the relatively low incidence of
endpoints, which limited the use of covariates in the
regression models. Another limitation is that we did not
collect urine samples. Consequently, it was not possible
to investigate the associations between the cysC-crea
ratio and urinary parameters, such as albuminuria.
Therefore, albuminuria could not be included as a
covariate in the regression model. Finally, we only
included Caucasian participants. The results can thus
not be extrapolated to populations of different origin.
However, we do not believe that these limitations
invalidate our findings.
In conclusion, this study is the first to provide refer-
ence intervals for the serum cysC-crea ratio for seniors.
Several associated factors were also identified. Finally,
we identified the cysC-crea ratio as a predictor of mor-
tality and morbidity. This result may be due to the selec-
tive retention of signaling molecules in individuals with
diminished filtration quality.ACKNOWLEDGMENTS
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Supplementary Table 1. Reference intervals for the CKD-EPI eGFRCys/eGFRCrea ratio (given as %) stratified
according to age and sex
Age
Females Males
Subjects Lower limit Upper limit Subjects Lower limit Upper limit
60–64 130 79 (75–83) 137 (133–142) 126 78 (71–85) 147 (140–154)
65–69 173 76 (72–79) 139 (135–143) 154 76 (70–82) 144 (139–150)
70–74 147 71 (59–81) 140 (129–152) 139 79 (76–84) 135 (132–138)
75–79 106 69 (65–74) 134 (129–139) 87 74 (69–79) 142 (136–147)
80–84 66 68 (64–73) 121 (117–125) 61 69 (64–74) 129 (123–135)
$85 29 72 (65–79) 121 (115–127) 16 63 (52–73) 134 (118–145)
Abbreviation: eGFR, estimated glomerular filtration rate.
Upper and lower limits are provided with 90% confidence intervals in parentheses. Reference intervals overlap substantially. Combined sex-
specific reference intervals are 72 (69–75)% to 136 (133–140)% for women (n 5 653) and 75 (73–78) to 141 (138–143)% for men (n 5 583). A
sex- and age-independent reference interval is 74 (71–76)% to 139 (137–141)%.
Supplementary Table II. Reference intervals for the CAPA/LMrev eGFRCys/eGFRCrea ratio (given as %) stratified
according to age and sex
Age
Females Males
Subjects Lower limit Upper limit Subjects Lower limit Upper limit
60–64 130 88 (84–92) 157 (151–161) 126 83 (77–89) 156 (150–162)
65–69 173 85 (81–89) 160 (155–164) 154 81 (75–88) 155 (149–162)
70–74 147 82 (69–93) 162 (150–175) 139 89 (85–93) 146 (143–150)
75–79 106 82 (77–88) 159 (152–165) 87 78 (69–88) 162 (153–171)
80–84 66 84 (79–90) 147 (141–152) 61 83 (78–89) 147 (141–154)
$85 29 91 (81–102) 157 (148–164) 16 78 (66–91) 161 (144–174)
Abbreviations: eGFR, estimated glomerular filtration rate; LMrev, Lund-Malm€o revised equation.
Upper and lower limits are provided with 90% confidence intervals in parentheses. Reference intervals overlap substantially. Combined sex-
specific reference intervals are 85 (81–88)% to 158 (154–161)% for women (n 5 653) and 83 (80–86)% to 153 (150–156)% for men (n 5 583). A
sex- and age-independent reference interval is 84 (82–86)% to 156 (153–158)%.
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Supplementary Fig 1. (A) The distribution of eGFRCys/eGFRCrea as
estimated by CKD-EPI (upper) and CAPA/Lund-Malm€o revised
(CAPA/LMrev; lower) are shown as boxplots with median, interquar-
tile range, 10th and 90th percentile, and outliers. The prevalence of
participants is 0.7% (CKD-EPI) and 0.2% (CAPA/LMrev) at a ratio
of ,60%, 2.2% (CKD-EPI) and 0.3% (CAPA/LMrev) at a ratio of
,70%, and 6.7% (CKD-EPI) and 1.6% (CAPA/LMrev) at a ratio
,80%. (B) Displays the distribution of cystatin C/creatinine (mg/
mmol) times a factor of 10,000. eGFR, estimated glomerular filtration
rate.
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